Cite
MLA Citation
D.S. Hong et al.. “Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions.” European journal of cancer, vol. 72, n.d., pp. S148–. http://access.bl.uk/ark:/81055/vdc_100041521804.0x000009